ArticleBrain sciences2021
SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
- Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.Brain sciences · 2025Article
- Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson's disease: a narrative review and expert opinion.Therapeutic advances in neurological disorders · 2025Review
- Long-Term Real-World Experience with Safinamide in Patients with Parkinson's Disease.Brain sciences · 2024Article
- Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.Neural regeneration research · 2024Review
- Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.Brain sciences · 2023Review
- Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.Current neuropharmacology · 2023Review
- Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.Patient related outcome measures · 2023Review
- Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.NPJ Parkinson's disease · 2022Article
- A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey.Parkinson's disease · 2022Article
- Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.Journal of Parkinson's disease · 2022Review
- Pain Improvement in Parkinson's Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study.Journal of personalized medicine · 2021Article
- Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.Brain sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations.
methodsRetrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018-February 2019). All were assessed with Scale for Outcomes in Parkinson's disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA-).
resultsFrom 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA-. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA- group remained unchanged.
conclusionsSafinamide could be helpful in the improvement of urinary symptoms in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.